Aktualne możliwości leczenia chorych na dnę moczanową*

Irena Zimmermann-Górska

2/2009 vol. 47

Pobierz cytowanie

PRACA PRZEGLĄDOWA

Aktualne możliwości leczenia chorych na dnę moczanową*

Irena Zimmermann-Górska

Więcej

Ukryj

Data publikacji online: 10-06-2009

Reumatologia 2009;47(2):75-81

Artykuł (PDF)

Referencje (63)

SŁOWA KLUCZOWE

dna moczanowa

hiperurykemia

STRESZCZENIE

W pracy przedstawiono możliwości leczenia dny w poszczególnych okresach objawów klinicznych oraz postępowanie w przypadkach bezobjawowej hiperurykemii.

REFERENCJE (63)

Keenan RT, O’Brien WR, Crettenden DR, et al. Gout management in a primary care setting: evidence for possible suboptimal treatment. ACR/ARHP Scientific Meeting, 08, program book supplement, 11. .

Google Scholar

Roubenoff R. Gout and hyperuricemia. Rheum Dis Clin North Am 1990; 16: 539-550. .

Google Scholar

Singh G, Dabbous O, Vadhavkar S, et al. Not only a swollen big toe: increasing all-cause hospitalizations in patients with gout in the United States: 1988-2005. Ann Rheum Dis 2008; (67 Suppl II); 96-97. .

Google Scholar

Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008; 67: 960-966. .

Google Scholar

Symmons D, Turher G, Webb R, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 2002; 41: 793-800. .

Google Scholar

Mikuls TR, Farrar JT, Bilker WD, et al. Gout epidemiology: results from the UK General Pracice Database, 1990-1999. Ann Rheum Dis 2005; 64: 267-272. .

Google Scholar

Riedel AA, Nelson M, Wallace K, et al. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 2004; 10: 308-314. .

Google Scholar

Wortmann RL. Management of hyperuricemia. Arthritis and Allied Conditions. A Textbook of Rheumatology. Koopmann WJ (ed.), 13th ed. Williams & Wilkins, Baltimore 1996; 2073-2081. .

Google Scholar

Wortmann RL, Kelley WN. Gout and hyperuricemia. Kelley’s Textbook of Rheumatology. Harris ED, Budd RC, Firestein GS, Genovese MC, Sergent JS, Ruddy S, Slegde CB (eds), 7th ed. Elsevier Saunders, Philadelphia 2005; 1402-1429. .

Google Scholar

10.

Choi HK. Dietary risk factors for rheumatic diseases. Curr Opin Rheumatol 2005; 17: 141-146. .

Google Scholar

11.

Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363: 1277-1281. .

Google Scholar

12.

Choi HK, Mount DB, Reginato AM; Pathogenesis of gout. Ann Intern Med 2005; 143: 499-516. .

Google Scholar

13.

Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-521. .

Google Scholar

14.

Netea MG, Kullberg BJ, Blok WL, et al. The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood 1997; 89: 577-582. .

Google Scholar

15.

Patterson RA, Horsley ET, Leake DS. Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: important role of uric acid. J Lipid Res 2003; 44: 512-521. .

Google Scholar

16.

Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2205; 67: 1739-1742. .

Google Scholar

17.

Lippi G, Montagnana M, Franchina M, et al. The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta 2008; 392: 1-7. .

Google Scholar

18.

Burack DA, Griffith BP, Thompson ME, Kahl LE. Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. Am J Med 1992; 92: 141-146. .

Google Scholar

19.

Kittleson MM, Bead V, Fradley M, et al. Elevated uric acid levels predict allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant 2007; 26: 498-503. .

Google Scholar

20.

Zhang W, Doherty M, Pasqual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1301-1311 (także: Medycyna Praktyczna 2007; 6: wydanie specjalne – 6/2007; 39-48). .

Google Scholar

21.

Schlesinger N, Norquist JM, Boice JA, Watson DJ. Serum urate during acute gouty arthritis attacks. Ann Rheum Dis 2008; 67 (Suppl II): 97. .

Google Scholar

22.

European Society of Hypertension – European Society of Cardiology. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053. .

Google Scholar

23.

Caliskan M, Erdogan D, Gullu H, et al. Association between serum uric acid levels and coronary flow reserve in hypertensive patients without concomitant risk factors. Blood Press 2006; 16: 254-261. .

Google Scholar

24.

Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005; 45: 18-20. .

Google Scholar

25.

Schachter M. Uric acid and hypertension. Curr Pharm Des 2005; 11: 4139-4143. .

Google Scholar

26.

Verdecchia P, Schillaci G, Reboldi G, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000; 36: 1072-1078. .

Google Scholar

27.

Madsen TE, Muhlenstein JB, Carlquist JF, et al. Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease. Am J Nephrol 2005; 25: 45-49. .

Google Scholar

28.

Niskanen LK, Laksonen DE, Nyyssönen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164: 1546-1551. .

Google Scholar

29.

Strasak A, Ruttmann E, Brant L, et al. VHM&PP Study Group. Serum uric acid and risk of cardiovascular mortality, a prospective long-term study of 83683 Austrian men. Clin Chem 2008; 54: 273-284. .

Google Scholar

30.

Fang J, Alderman MH. Serum uric acid and cardiovascular mortality in the NHANES 1 epidemiologic follow-up study. 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 293: 2404-2410. .

Google Scholar

31.

Mazza, Pesina AC, Pavei A, et al. Predictors of stroke mortality in elderly people from the general population. The Cardiovascular Study in the Elderly. Eur J Epidemiol 2001; 17: 1097-1104. .

Google Scholar

32.

Milinis HJ, Kalantzi KJ, Goudevenos JA, et al. Serum uric acid levels and risk for acute ischaemic non-embolic stroke in elderly subjects. J Intern Med 2005; 258: 435-441. .

Google Scholar

33.

Schretlen DJ, Inscore AB, Yannorsdall TD, et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology 2007; 69: 1418-1423. .

Google Scholar

34.

Choi HK, Ford ES, Li S, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007; 57: 109-115. .

Google Scholar

35.

Puig JG, Martinez MA. Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol 2008; 20: 187-191. .

Google Scholar

36.

Yoo TW, Sung KC, Shin HS, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 2005; 69: 928-933. .

Google Scholar

37.

Doehner W, Schoene, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002; 105: 2619-2624. .

Google Scholar

38.

Perez-Ruiz F, Schlesinger N. Management of gout. Scand J Rheumatol 2008; 37: 81-89. .

Google Scholar

39.

Zhang W, Doherty M, Bardin J, et al. EULAR evidence based recommendations for gout. Part II. Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-1324 (także: Medycyna Praktyczna 2007/6; wydanie specjalne, 39-48). .

Google Scholar

40.

Morris I, Varughese G, Mattingly P. Colchicine in acute gout. Br Med J 2003; 327: 1275-1276. .

Google Scholar

41.

Terkeltaub R, Furst DE, Bennett K, et al. Low dose (1.8 mg) vs high dose (4.8 mg) oral colchicine regimens in patients with acute gout flare in a large, multicenter, randomized, double-blind, placebo-controlled, parallel group study. Arthritis Rheum 2008; 58 (Suppl): 879-880. .

Google Scholar

42.

Simkin PA, Gardner GC. Colchicine use in cyclosporine treated transplant recipiens: how little is too much? J Rheumatol 2000; 27: 1334-1337. .

Google Scholar

43.

Fernandez C, Noguera R, Gonzales JA, Pasqual E. Treatment of acute attacks of gout with small doses of intraarticular tiramcinolone acetonide. J Rheumatol 1999; 26: 2285-2286. .

Google Scholar

44.

Taylor CT, Brooks NC, Kelley KW. Corticotropin for acute management of gout. Ann Pharmacother 2006; 35: 365-368. .

Google Scholar

45.

Petersel D, Schlesinger N. Treatment of acute gout in hospitalized patients. J Rheumatol 2007; 34: 1566-1568. .

Google Scholar

46.

Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007; 46: 1327-1374. .

Google Scholar

47.

Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effects of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002; 47: 356-360. .

Google Scholar

48.

Becker MA, Schumacher HR JR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450-2461. .

Google Scholar

49.

Pasqual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007; 66: 1056-1058. .

Google Scholar

50.

Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51: 321-325. .

Google Scholar

51.

Becker M, Schumacher HR. Jr, Espinosa L, et al. A phase 3 randomised, controlled, multicenter, double-blind trial (RCT) comparing efficacy and safety of daily Febuxostat (FEB) and Allopurinol (ALLO) in subjects with gout. ACR/ARHP Scientific Meeting, 08 program book supplement, 57. .

Google Scholar

52.

Whelton A, MacDonald P, Lloyd E, Lademacher C. Beneficial relationship of serum urate (sUA) reduction and estimated glomerular filtration rate (eGFR) improvement/maintenance in hyperuricemic gout subjects treated for up to 5.5 years with Febuxostat (FEB). ACR/ARHP Scientific Meeting 08, program book supplement, 3. .

Google Scholar

53.

Becker MA, Treadwell EL, Baraf HS, et al. Immunoreactivity and clinical response to pegloticase (PGL): pooled data from GOUT1 and GOUT2, PGL phase 3 randomised, double blind, placebo-controlled trials. Arthritis Rheum 2008; 58 (Suppl): S880. .

Google Scholar

54.

Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008; 60: 59-68. .

Google Scholar

55.

Sundy JS, Baraf HS, Becker MA, et al. Efficacy and safety of intravenous (IV) Pegloticase (PGL) in subjects with treatment failure gout (TFG): Phase 3 results from GOUT1 and GOUT2. Arthritis Rheum 2008; 58 (Suppl): S400-401. .

Google Scholar

56.

Reinders MK, Haagsma O, Van Roon EN, et al. Dose-escalation of allopurinol versus benzbromarone in gout patients: a randomised controlled trial. Ann Rheum Dis 2008; 67 (Suppl II): 98. .

Google Scholar

57.

Feher MD, Hepburn AL, Hogarth MB, et al. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricemia and gout. Rheumatology 2003; 42: 321-325. .

Google Scholar

58.

Liberopoulos E, Christides D, Elisaf M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 2002; 20: 347. .

Google Scholar

59.

Sundy J, Terkeltaub R, Schumacher HR, et al. Placebo-controlled pilot study of rilonacept (IL-1 TRAP), a long acting IL-1 inhibitor, in refractory chronic active gouty arthritis. Ann Rheum Dis 2008; 67 (Suppl II): 97. .

Google Scholar

60.

Cheney W, Larson G, Lai Ch, et al. MEK inhibitor RDEA119 supresses inflammatory cytokine production induced by monosodium urate crystals. Arthritis Rheum 2008; 58 (Suppl): S879. .

Google Scholar

61.

Underwood M. Diagnosis and management of gout. Br Med J 2006; 332: 1315-1319. .

Google Scholar

62.

Wortmann RL. The management of gout: it should be crystal clear. J Rheumatol 2006; 33: 1921-1922. .

Google Scholar

63.

Pasqual E, Sivera T. Why is gout so poorly managed? Ann Rheum Dis 2007; 66: 1269-1270. .

Google Scholar

Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Wyślij swój artykuł

Archiwum

Dla autorów

Udostępnij

Wyślij mailem

ARTYKUŁ POWIĄZANY

Aktualizacja standardów leczenia
Dna moczanowa

Artykuł przeglądowy
Kliniczne maski związane z chorobami reumatycznymi wywoływanymi przez kryształy

Nowe leki w leczeniu dny moczanowej

Dna moczanowa – aktualne spojrzenie na diagnostykę i leczenie

Dna moczanowa – nowe możliwości diagnostyczne i terapeutyczne

Indeksy